Dr Charles Morris is a Medical Oncologist with over 20 years of cancer drug development experience in the pharmaceutical and biotechnology industries. Having gained clinical and research experience at The Christie Hospital in Manchester, UK, he joined Zeneca (later AstraZeneca) Pharmaceuticals where he was involved in the development of a number of oncology agents including fulvestrant and gefitinib. Having gained experience across all phases of drug development, he later joined Cephalon where he was Vice President Clinical Research, Oncology, helping to secure approvals for bendamustine in two hematology-oncology indications. He later became Chief Medical Officer at Allos Therapeutics – which was acquired by Spectrum Pharmaceuticals in 2012 – and then Chief Development Officer at ImmunoGen, Inc., leading the development of their proprietary pipeline of antibody drug conjugates. Dr Morris is a graduate of Sheffield University Medical School and is a Member of the Royal College of Physicians.